PDS Biotechnology

PDS Biotechnology CEO Frank Bedu-Addo discusses the Company's clinical progress and T-cell immunotherapy approach, as well as key trends across today's biotech environment in his interview with @pharmaboardroom. Read the full interview here: bit.ly/4teiC0p $PDSB

PDS Biotech will host a conference call and webcast to report financial results for the quarter and year ended December 31, 2025, and will provide a clinical programs and corporate update, on Monday, March 30th at 8:00 am ET. For details, visit: bit.ly/4bvXA7p $PDSB

March is #ColorectalCancerAwarenessMonth – and colorectal cancer rates are rising. At PDS Biotech, we're dedicated to improving outcomes by transforming how the immune system targets and fights cancer to create targeted treatments. Learn more: bit.ly/4rMK30c

March is #NationalColorectalCancerAwarenessMonth. The incidence of early onset colorectal cancer is expected to increase by more than 140% by 2030 according to @AmericanCancer. Learn more about colorectal cancer here: bit.ly/3PGCESs

Frank Bedu-Addo, PhD, President and CEO, comments on the VERSATILE-003 Phase 3 protocol amendment to include PFS as an interim primary endpoint for potential accelerated approval of PDS0101 in HPV16-positive head and neck cancer: bit.ly/4kPqG4D $PDSB

The adoption of a protocol amendment in PDS Biotech's Phase 3 VERSATILE-003 clinical trial enables potential shorter time to accelerated approval of PDS0101 in HPV16-positive head and neck cancer. Read more about the amended protocol: bit.ly/4kPqG4D $PDSB

PDS Biotech today announced the adoption of a protocol amendment to its Ph. 3 VERSATILE-003 trial, including PFS as an interim primary endpoint to support a potential accelerated approval pathway for PDS0101 in HPV16+ R/M head and neck cancer. bit.ly/4kPqG4D $PDSB

This #WorldCancerDay, PDS Biotech stands with those affected by cancer. We're committed to developing novel immunotherapies based on our T cell stimulating platforms that have the potential to transform treatment and bring new hope to patients around the world. bit.ly/2C4bCMA

Results from a @theNCI-led study of PDS01ADC presented at the @AACR special conference on innovations in prostate cancer showed a median PFS of 9.6 months in metastatic castration resistant prostate cancer patients. Read more: bit.ly/3Oasf0z $PDSB

Frank Bedu-Addo, PhD, President and CEO, comments on the presentation of preliminary results from the Company's Ph. 2 study of IL-12 tumor targeted immunocytokine (PDS01ADC) in mCRPC at the @AACR special conference on prostate cancer research: bit.ly/3Oasf0z $PDSB

PDS Biotech today announced that results of a @theNCI-led study of the Company’s investigational IL-12 tumor targeted immunocytokine, PDS01ADC, were presented at the @AACR special conference on prostate cancer research. Read more: bit.ly/3Oasf0z $PDSB

Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, comments on the issuance of a new U.S. patent for the Company's lead asset, PDS0101: bit.ly/4jQ7wLm $PDSB

When issued, PDS Biotech's new patent, combined with anticipated U.S. biologics exclusivity, should support approximately 20 years of market protection for PDS0101, which is currently being evaluated in the Phase 3 VERSATILE-003 clinical trial. bit.ly/4jQ7wLm $PDSB

PDS Biotech today announced that the U.S. Patent Office has issued a Notice of Allowance for the technology platform underlying the Company’s lead asset, PDS0101. Read more: bit.ly/4jQ7wLm $PDSB

Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, comments on the FDA's alignment on the use of Progression Free Survival (PFS) as a primary endpoint in the Phase 3 VERSATILE-003 clinical trial: bit.ly/49sJz81 $PDSB

The submission of a protocol amendment to the FDA follows a constructive Type C meeting held in Dec. 2025 to discuss the proposed accelerated approval pathway for PDS0101 in HPV16+ recurrent and/or metastatic Head and Neck Cancer. Read more: bit.ly/49sJz81 $PDSB

$PDSB's submitted protocol amendment changes PFS to a primary endpoint that can be evaluated earlier w/ significant statistical power, potentially providing the basis for accelerated approval of PDS0101. mOS remains the primary endpoint for full approval. bit.ly/49sJz81

PDS Biotech today announced FDA alignment on the use of progression free survival (PFS) as a primary endpoint. The Company has submitted a protocol amendment for its Phase 3 VERSATILE-003 clinical trial that changes the PFS endpoint to a primary endpoint. bit.ly/49sJz81 $PDSB

President and CEO of PDS Biotech, Frank Bedu-Addo, recently joined the Base to Base Biotech Podcast to discuss the growing prevalence of HPV16-related head and neck cancers and how our targeted immunotherapies aim to transform treatment. Listen here: apple.co/44Ei89Y $PDSB

Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotechnology, comments on the issuance of Patent No. 7783866 by the Japan Patent Office for PDS0101 granting broad composition of matter and methods of use claims: bit.ly/44CFzR5 $PDSB